27 results about "Sedative effect" patented technology

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition with a nerve soothing effect and a preparation method and application thereof. The traditional Chinese medicine composition with the nerve soothing effect comprises the following raw materials in parts by weight: 25-35 parts of gastrodia elata, 15-25 parts of codonopsis pilosula, 15-25 parts of spina date seeds, 10-20 parts of poria cocos, 25-35 parts of rhizoma alismatis, 5-15 parts of lotus seeds, 10-20 parts of polygala tenuifolia and 5-10 parts of liquorice. The formula is found to have a good effect on soothing the nerves, stabilizing the mind and treating anxiety and insomnia through a proper ratio.

2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2-oxopyrrolidin-1-yl)propanamide derivatives with R-configuration at the stereogenic center are disclosed, showing broad-spectrum protective activity in animal models of epileptic seizures, pain, depression and anxiety that are simultaneously devoid of undesirable sedative effects. Additionally, the disclosed derivatives have neuroprotective effects in the in vitro and in vivo studies.

The present invention discloses a class of 4-(1H)-imidazole derivatives represented by the following formula (I), their pharmaceutically acceptable salts, racemic mixtures, enantiomers, optical isomers and tautomers, as well as pharmaceutical compositions containing them, and their use as α2-adrenergic receptor agonists, especially as α 2A -agonists and their methods of use. Compared with the prior art, the compounds of the present invention show more potent agonist activity and higher selectivity for α 2A -AR, superior to the positive drug dexmedetomidine; and at the same time have a potent in vivo sedative effect. #imgabs0#

The utility model discloses a snore-ceasing patch, which relates to the technical field of medical supplies and comprises a snore-ceasing patch body, a cutting groove is arranged at the top end of the snore-ceasing patch body, and an arc-shaped groove is arranged on one side of the cutting groove. A first plaster sheet is arranged at the top end of the snore stopping sheet body and fixedly connected to the top end of the snore stopping sheet body, a second plaster sheet is arranged at the bottom end of the snore stopping sheet body, and absorbent cotton is arranged on the inner side of the second plaster sheet. The first plaster sheet is arranged at the top end of the snore stopping sheet body, mild medicine is arranged on the inner side of the first plaster sheet, the sedation effect can be effectively improved after a patient inhales the medicine, the sleep quality is improved, the second plaster sheet is arranged at the bottom end of the snore stopping sheet body, the medicine cotton is arranged on the inner side of the second plaster sheet, and the snore stopping sheet is convenient to use. The refreshing agent is arranged in the pillow, so that the respiratory capacity in sleep can be effectively increased, the breathing quality is improved, and the sleep quality is effectively improved.

Compositions comprising at least 10% of a compound of formula (I) by weight, at least 10% of a compound of formula (II) by weight, or at least 10% by weight of a combination of a compound of formula (I) and a compound of formula (II), are disclosed herein. Methods for administering the compositions are disclosed herein. The methods can be used to produce a calming effect, produce an analgesic effect, manage pain, treat cough, treat anxiety, treat depression, treat opioid use disorder, and / or to treat opioid withdrawal in a subject.

The breathing system for a patient to inhale a substance from, the substance being for analgesic, anaesthetic and / or sedative effect on the patient, comprises a patient airway interface, an adding means 16, a user control 18 and a control means. The patient airway interface is mountable on the patient so that inhaling and exhaling occur through the patient airway interface consecutively and repetitively. The adding means is for adding the substance to gas to be inhaled, wherein the substance is provided in volatile liquid form, and vaporisation of the substance into the gas is facilitated. The user control is coupled to the control means to provide input thereto in response to operation of the user control. The user control can be mountable to the hand of a patient so that the patient can operate the user control in a user action, thereby to send information indicative of substance being wanted to the control means, and / or in response to stimulus.

The invention belongs to the technical field of medicines, and particularly relates to combined application of nicotine and theobromine in relieving bipolar affective disorder as well as a product and a preparation method of the product. The problems that traditional western medicines are large in curative effect fluctuation, have addiction risks, are obvious in side effects and the like are solved, the anti-anxiety characteristic of nicotine and the analgesic and sedative effects of theobromine are used for synergistically exerting a multi-dimensional intervention effect, and curative effect superposition is achieved. The invention also determines the ratio of nicotine to theobromine (the mass ratio of nicotine to theobromine is 1: 100-1000), provides a reliable basis for clinical application, and is beneficial to improving the treatment effect. According to the scheme, the technical blank that natural components are combined to be used for treating bipolar affective disorder is filled, a brand new path is provided for intervention of the disease, and important theoretical exploration value and practical application significance are achieved.

The invention relates to a new application of N, N-diethyl-2-hydroxyphenylacetamide. It is unexpectedly found that N, N-diethyl-2-hydroxyphenylacetamide or a derivative thereof of the present application has a sedative effect, so that N, N-diethyl-2-hydroxyphenylacetamide or a derivative thereof can be used for sedation or prevention and / or treatment of diseases or conditions associated with a non-sedative state. According to the present invention, the N, N-diethyl-2-hydroxyphenylacetamide or the derivative thereof can be adopted as the active component of the sedative drug, and can provide significant sedative and hypnotic effects on mice, and the research results show that DEM has significant inhibition effects on the L-Glu content in the cerebral cortex and other parts of the brain, such that more choices can be provided for the development of the sedative drug.

A preparation method of an external patch for preoperative sedation relates to the field of medical preparations containing organic effective components, and sequentially comprises the steps of preparing a main component pretreatment substance, preparing a matrix solution, preparing an ointment-containing paste and synthesizing the patch, the preparation method of the main component pretreatment substance comprises the following steps: preparing a mixed liquid by taking dexmedetomidine hydrochloride and floperidol as main components, carrying out spray granulation to obtain a composite solid dispersion, crushing the composite solid dispersion into powder, and mixing and stirring the powder with paraffin oil and superfine silica powder. In the patch prepared from dexmedetomidine hydrochloride and floperidol, the effective components can quickly penetrate through the skin mucous membrane, so that the effect of quickly taking effect is achieved, and a good sedative effect is achieved. The dispersion uniformity of main components in the patch is excellent, the RSD is within 2%, and the effect consistency of the patch is guaranteed. According to the dexmedetomidine hydrochloride tablet, the stability of dexmedetomidine hydrochloride is effectively improved, components are prevented from being decomposed in the long-term storage process, other impurities are not generated, and the shelf life is effectively prolonged to 24 months.

2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2-oxopyrrolidin-1-yl)propanamide derivatives with R-configuration at the stereogenic center are disclosed, showing broad-spectrum protective activity in animal models of epileptic seizures, pain, depression and anxiety that are simultaneously devoid of undesirable sedative effects. Additionally, the disclosed derivatives have neuroprotective effects in the in vitro and in vivo studies.

The present invention relates to a new substance with physiological activity, specifically a new substance produced during microbial mutagenesis and its application, belonging to the field of biotechnology. The new substance with physiological activity is a compound of Formula I, which exhibits significant tyrosinase inhibition and sedative effects. The compound of Formula I can be added to cosmetics as a functional ingredient to prevent melanin production caused by excessive tyrosinase activity, resulting in products with whitening properties. It can also be used as a sedative drug to treat stress, improve sleep, combat anxiety, and relieve irritability.

The invention relates to application of cannabidiol in preparation of a medicine for adjuvant therapy of hyperthyroidism, and belongs to the technical field of biological medicine. The invention aims to provide novel medical application of cannabidiol, namely application of cannabidiol in preparation of a medicine for adjuvant therapy of hyperthyroidism. Animal model in-vivo experiments prove that cannabidiol has a sedative effect on hyperthyroidism mice, can inhibit hyperactivity caused by hyperthyroidism and effectively relieve symptoms such as easy excitation, dysphoria and insomnia, is beneficial to emotion stabilization and creates favorable conditions for treatment of hyperthyroidism. Cell in-vitro experiments prove that cannabidiol can effectively block a stress signal channel triggered by corticosterone, relieve the stress reaction degree of liver cells, relieve the liver burden and promote liver function recovery, and a new intervention thought is provided for adjuvant therapy of hyperthyroidism liver injury.

The invention discloses a cinnabar nano-vesicle gel emplastrum with a tranquilizing and calming effect as well as a preparation method and application of the cinnabar nano-vesicle gel emplastrum. The method comprises the following steps: preparing target peptide modified cinnabar nano-vesicles by adopting a film dispersion method; dissolving cinnabar nano-vesicles in PBS as a phase C for later use; mixing the second framework material, the tackifier, the filler and the humectant to obtain a phase A; mixing a cross-linking agent, a cross-linking regulator, a penetration enhancer and a bacteriostatic agent to obtain a phase B; stirring and mixing the phase A, the phase B and the phase C, coating a non-woven fabric with the mixture, placing the non-woven fabric at room temperature, and covering the non-woven fabric with an anti-sticking film to obtain the target peptide modified cinnabar nano-vesicle gel emplastrum. The cinnabar nano-vesicle gel emplastrum can promote intestinal microorganisms to generate 5-hydroxytryptamine (5-HT), so that a cerebral cortex 5-HT1AR-cAMP pathway is activated, brain activity is adjusted, sleep conditions are improved, the cinnabar nano-vesicle gel emplastrum has slow release property, skin penetrability and intestinal tract targeting property, and the insecurity caused by direct oral administration of cinnabar into blood circulation is also solved.

To provide an adjustment device capable of adjusting a biological rhythm and a life rhythm of an object person.SOLUTION: An adjustment device (40) includes a spray device (41) that supplies a substance having an awakening effect or a sedative effect to an object space (S) in which an object (T) is present, and a control device (100). The control device (100) controls the spray operation of the spray device (41) based on a biological rhythm of an object (T) and reference data serving as a reference of the biological rhythm, or based on a life rhythm of the object (T) and reference data serving as a reference of the life rhythm.SELECTED DRAWING: Figure 3

The application discloses a benzodihydrofuran compound, a pharmaceutical composition thereof and application. The application provides a compound as shown in formula I or a pharmaceutically acceptable salt thereof. The compound has a sedative effect and helps to relieve the mania symptoms of patients with mental diseases.

This invention relates to a levotetrahydropalmatine citrate, its preparation method, and its applications, belonging to the field of pharmaceutical technology. This invention provides a levotetrahydropalmatine citrate. Studies have shown that compared to other salt forms, the citrate form of levotetrahydropalmatine significantly improves its solubility. Furthermore, research has confirmed that levotetrahydropalmatine citrate can significantly reduce drug relapse preferences, with efficacy comparable to or even better than the injectable form, without causing significant adverse reactions and exhibiting good safety. Simultaneously, the sedative effect of levotetrahydropalmatine citrate is far superior to other salt forms. In addition, levotetrahydropalmatine citrate has therapeutic effects on sleep disorders, effectively shortening sleep onset time, increasing sleep duration, and improving sleep quality. Therefore, the levotetrahydropalmatine citrate provided by this invention has broad application prospects in the preparation of drugs for sedation, analgesia, treatment of sleep disorders, and treatment of drug addiction.

The application discloses a potent non-sleepy antiemetic and anti-motion sickness pharmaceutical composition and application thereof, and belongs to the technical field of medicines.The composition comprises five active ingredients of pheniramine maleate, caffeine, vitamin B6, scopolamine and lidocaine.Through the synergistic effect of the components, the composition can strongly inhibit the dizziness and vomiting reaction caused by the vestibular stimulation, and meanwhile, the sedative effect of the antihistamine drug is antagonized by caffeine, so that the side effect of sleepiness of the traditional anti-motion sickness drug is avoided while the anti-motion effect is ensured.Experiments show that the effect of the composition in an anti-motion sickness animal model is obviously better than that of each single drug and a conventional positive control drug.The composition can be used for preparing various pharmaceutical preparations for preventing and treating motion sicknesses such as car sickness, ship sickness and aircraft sickness, and has important clinical application value.

The invention discloses a formula of agilawood volatile oil for preparing biological medicines and a preparation method of the agilawood volatile oil. According to the traditional Chinese medicine composition, the agilawood volatile oil has a natural calming effect, can help relieve tension, anxiety and pressure, and has a good regulating effect on a nervous system. The aroma of the agilawood volatile oil is beneficial to improving the sleep quality and has a certain adjuvant therapy effect on insomnia patients. The agilawood volatile oil is capable of refreshing and enhancing attention, and is suitable for being used during learning or working. The agilawood volatile oil has certain anti-inflammatory and antibacterial effects and can be used for treating slight skin inflammation or promoting wound healing. Different kinds of plant essential oil have different pharmacological effects, for example, lavender essential oil has the effects of resisting depression and promoting sleep, and tea tree essential oil has the effects of resisting bacteria and diminishing inflammation, so that the overall curative effect of the medicine can be enhanced by combining the lavender essential oil and the tea tree essential oil with the agilawood volatile oil.

The utility model provides a nasal cavity anesthesia dosing device which comprises a dose adjusting part, a spray injection part and a protective cap, the dose adjusting part comprises a first shell, a knob sleeve and a spiral push rod, and the required medicament dose is selected through the knob sleeve and the spiral push rod; accurate administration can be carried out according to dosage requirements of different patients; the spray injection part comprises a second shell, a liquid medicine core and a spray head, the interior of the second shell is hollow, a containing space for containing medicine is formed in the second shell, and before use, medical staff can detach the first shell from the second shell and place the liquid medicine core in the second shell to be fixed and replaced; the spiral push rod can extend into the second shell and abut against the liquid medicine core. The rotary knob sleeve is arranged at the tail of the dosage adjusting part and connected with the spiral push rod, the spiral push rod can push out liquid medicine in the liquid medicine core, and vaporific liquid medicine with the corresponding injection milliliter number is pushed out through the atomizing spray head to reach the surface of the mucous membrane of the nasal cavity, so that the anesthesia and sedation effects are achieved.

The present invention provides a pharmaceutical composition comprising a local anesthetic and fospropofol disodium, a preparation method and use thereof, and a combination drug, belonging to the field of pharmaceutical preparations. The pharmaceutical composition and the combination drug have both analgesic and sedative effects. Through the additive or synergistic effect between the drugs, the onset time of fospropofol disodium can be shortened, the pharmacodynamic effect can be enhanced, the drug dosage can be reduced, the pH value of the fospropofol disodium solution can be improved, adverse reactions during anesthesia induction can be alleviated, the number of medications required by anesthesiologists can be reduced, and the anesthesia induction process can be made more convenient, thereby achieving a more ideal anesthetic effect.

The application belongs to the technical field of biological medicine, and specifically discloses application of benserazide hydrochloride in preparation of anxiolytic drugs. The application first finds that benserazide hydrochloride plays an anxiolytic role by regulating the kynurenine metabolic pathway. Animal experiments prove that benserazide hydrochloride can promote the generation of kynurenine and its downstream metabolite 3-hydroxyanthranilic acid, and maintain the stable level of 3-hydroxykynurenine, thereby improving the function of the metabolic pathway and restoring the nervous system homeostasis. Behavioral experiments show that benserazide hydrochloride can increase the exploration behavior of zebrafish and reduce the avoidance behavior, and meanwhile, does not cause inhibition of motor function or sedative effect, and shows good safety and selectivity. The application provides a theoretical basis and a new drug source for the prevention and / or treatment of anxiety.

The invention relates to the technical field of plant extracts and mineral extracts, and particularly discloses a sleep promoting composition for balancing a magnetic field and a microenvironment and a preparation and use method thereof.The sleep promoting composition is prepared from, by weight, 10-30 parts of plant powder, 0.5-1.7 parts of mercuric sulfide and 2-8 parts of a bonding matrix; wherein the plant powder comprises at least one of a component A for promoting dopamine secretion, a component B with an aromatic curative effect and a component C with a sedative effect; the adhesive matrix contains a silicate. Natural plants and minerals are adopted, the mind tranquilizing and sleep promoting effects provided by the plants and the improvement of the minerals on a micro magnetic field of a sleep environment are utilized, the traditional Chinese medicine does not need to be taken and is not close to the skin, sleep disorders are effectively improved, and drug dependence is reduced.

The application provides a new compound with local anesthesia and general deep sedation function and medical use. The new compound has the structure shown in the following formula: The compound has local anesthesia and also exhibits a unique general sedative effect, suggesting that it has general anesthesia potential, and its rapid onset and recovery characteristics make it possible to be used for developing a new intravenous anesthetic.

2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2-oxopyrrolidin-1-yl)propanamide derivatives with R-configuration at the stereogenic center are disclosed, showing broad-spectrum protective activity in animal models of epileptic seizures, pain, depression and anxiety that are simultaneously devoid of undesirable sedative effects. Additionally, the disclosed derivatives have neuroprotective effects in the in vitro and in vivo studies.

The utility model discloses an analgesia pump capable of being used in a double-bin switching mode, and belongs to the field of analgesia pumps. The analgesia pump capable of being used in the double-bin switching mode comprises an analgesia pump component, the analgesia pump component comprises a shell structure and a clamp structure arranged at the upper end of the shell structure, a switching structure is arranged in the shell structure, and the lower end of the switching structure is connected with an infusion structure. The shell structure can be clamped to the clothes of a patient through the clamp structure, carrying is convenient, flowing of medicine in the liquid storage bin can be controlled through the self-control valve, so that analgesic medicine and sedative can flow into the infusion structure by switching the infusion catheter and the three-way connector respectively, and the infusion effect is good. The double bins can be used at the same time according to the illness state and pain of the patient, the double bins can also have the sedative effect, and the double bins have the advantages of helping the patient to sleep, relieving mood and facilitating recovery of the patient.

A steroid compound for treating a central nervous system disease, a method for preparing same, and use and a pharmaceutical composition thereof. The steroid compound has a 9β,10α structure and has the structural formula depicted as Formula I in this document. The steroid compound acts as a GABA regulator, prolongs the opening time of a chloride ion channel activated by GABA, adjusts the excitability of the central nervous system (CNS), and treats and prevents CNS-related diseases. Besides, the 9β,10α steroid compound of the present invention has a sedative effect and can be used as a sedative.